UTI Healthcare Fund - Direct Plan - Growth Option
UTI Asset Management Company Private Limited · Direct Plan · Growth
Fund overview
1% on or before 30D, Nil after 30D
Returns & rankings
| Period | Fund Returns | Category Avg. | Rank | VS Category |
|---|---|---|---|---|
| … | ||||
Green = fund outperformed the category average for that period; red = underperformed. Periods under 1 year always show absolute (non-annualised) returns. Past performance does not guarantee future returns.
Return calculator
One-time investment
₹5,000
| Over the past | Total investment | Would've become | Returns |
|---|---|---|---|
| 1 Year | ₹5,000 | ₹5,787 | +787 |
| 3 Years | ₹5,000 | ₹7,753 | +2,753 |
| 5 Years | ₹5,000 | ₹10,386 | +5,386 |
Calculated using the fund's annualised return since inception (15.7% p.a.) as period-wise historical returns aren't available in the current feed. Actual returns fluctuate and are not guaranteed. Mutual fund investments are subject to market risks.
Holdings
44 securitiesTop 10 holdings make up 43.5% of the portfolio.
| Security | Sector | Market Cap | Weight |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Pharmaceuticals & Biotechnology | Large Cap | 7.62% |
| Divi'S Laboratories Ltd | Pharmaceuticals & Biotechnology | Large Cap | 6.15% |
| Cash/Bank/Net Current Assets/(Liabilities) | Cash/Deposits/Margins/Treps/Repo/Swaps | — | 5.85% |
| Dr. Reddys Laboratories Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 5.24% |
| Ajanta Pharma Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 4.81% |
| Gland Pharma Ltd | Pharmaceuticals & Biotechnology | Small Cap | 4.06% |
| Alkem Laboratories Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 3.70% |
| Apollo Hospitals Enterprises Ltd | Healthcare Services | Large Cap | 3.03% |
| Caplin Point Laboratories Ltd | Pharmaceuticals & Biotechnology | Small Cap | 3.02% |
| Global Health Ltd | Healthcare Services | Small Cap | 2.96% |
Portfolio Allocation
Equity / Debt / Cash
Total Value
₹1,430 Cr
Market Cap Split
Total Value
100%
Equity sector allocation
Total Value
₹1,346 Cr
Exit load, stamp duty & tax
01-Jan-13
1% on or before 30D, Nil after 30D
0.005% (from July 1st, 2020)
Taxation depends on the fund category and holding period. Consult the scheme document or a tax advisor for details.
Risk & Performance Ratios (1Y)
| Standard Deviation | 14.73% |
| Beta | 0.90 |
| Sharpe Ratio | 2.94 |
| Sortino Ratio | -0.02 |
| Treynor Ratio | 0.48 |
| Jensen's Alpha | 3.43 |
| Information Ratio | -0.02 |
| R-Squared | 96.02% |
| Max Drawdown | -3.53% |
| Upside Capture | 93.46% |
| Downside Capture | 70.21% |
Fund management
Scheme Details
Investment objective
The Primary Objective Of The Scheme Is To Generate Long Term Capital Appreciation By Investing Predominantly In Equity And Equity Related Securities Of Companies/Institutions Engaged In The Healthcare Services Sector. However, There Can Be No Assurance Or Guarantee That The Investment Objective Of The Scheme Would Be Achieved.
Fund house
UTI Asset Management Company Private Limited
Frequently asked questions
What is the NAV of UTI Healthcare Fund - Direct Plan - Growth Option?
The NAV of UTI Healthcare Fund - Direct Plan - Growth Option is ₹358.94 as of 21 Oct 2026. NAV is updated at the end of every trading day.
How much expense ratio is charged by UTI Healthcare Fund - Direct Plan - Growth Option?
The expense ratio charged by UTI Healthcare Fund - Direct Plan - Growth Option is 1.34%.
What is the Min. SIP of UTI Healthcare Fund - Direct Plan - Growth Option?
The minimum SIP investment in UTI Healthcare Fund - Direct Plan - Growth Option is ₹500 per month.
What is the Min. Lumpsum of UTI Healthcare Fund - Direct Plan - Growth Option?
The minimum lumpsum investment in UTI Healthcare Fund - Direct Plan - Growth Option is ₹5,000.
What is the Exit Load of UTI Healthcare Fund - Direct Plan - Growth Option?
The exit load for UTI Healthcare Fund - Direct Plan - Growth Option is: 1% on or before 30D, Nil after 30D
.svg){kind=small}